Loss of expression of E-cadherin and β-catenin is associated with progression of pulmonary adenocarcinoma

The aim of the present study was to determine the association of loss of membranous expression of epithelial (E)-cadherin and beta-catenin with the progression of pulmonary adenocarcinoma. The expression of E-cadherin and beta-catenin was examined in 154 cases of pulmonary adenocarcinoma, including 49 cases of atypical adenomatous hyperplasia (AAH), 40 cases of bronchioloalveolar carcinoma (BAC), 42 cases of BAC-dominant type of adenocarcinoma with mixed subtypes (early MX) and 23 cases of BAC-recessive type of adenocarcinoma with mixed subtypes (overt MX), by immunohistochemistry. E-cadherin expression was positive in all cases of AAH, in 37 cases (92.5%) of BAC and in 34 cases (81.0%) of early MX, while it was positive in three cases (13.0%) of overt MX. beta-Catenin expression was positive in 47 cases (95.9%) of AAH, in 28 cases (70%) of BAC, in 32 cases (76.2%) of early MX and in 11 cases (47.8%) of overt MX. The rates of expression of E-cadherin and beta-catenin among cases of AAH, BAC, early MX and overt MX were significantly reduced. Loss of expression of E-cadherin and beta-catenin may play an important role in the progression of pulmonary adenocarcinoma, and these events occur before structural destruction of the alveolar wall by invasion of carcinoma cell.